FindTrial
Sign In

Autoinjector

DEVICE9 trials

Sponsors

Hoffmann-La Roche, Momenta Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., AbbVie, AstraZeneca

Conditions

Allergic ReactionAtheromaAtherosclerotic PlaqueBleedingCoronary Artery DiseaseHealthy Adult ParticipantsHealthy Participants StudyHepatitis C, Chronic

Phase 1

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
CompletedNCT01087944
Hoffmann-La RocheHepatitis C, Chronic
Start: 2010-03-31End: 2010-06-30Updated: 2016-02-09
Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab
CompletedNCT05339100
AstraZenecaHealthy Participants Study
Start: 2022-03-22End: 2023-04-13Updated: 2023-05-11
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
RecruitingNCT07635095
Astria Therapeutics, Inc.Healthy Adult Participants
Start: 2026-04-21End: 2026-12-01Target: 180Updated: 2026-06-09

Phase 2

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis
CompletedNCT03193957
Samsung Bioepis Co., Ltd.Rheumatoid Arthritis
Start: 2017-05-15End: 2017-09-25Updated: 2017-10-13

Phase 3

Usability of an AI for M923 in Subjects With Moderate to Severe RA
CompletedNCT02722044
Momenta Pharmaceuticals, Inc.Rheumatoid Arthritis
Start: 2016-04-30End: 2017-02-21Updated: 2018-05-16
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
CompletedNCT03875508
AbbViePsoriasis
Start: 2019-06-04End: 2020-08-25Updated: 2021-05-11
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
CompletedNCT07155668
Viridian Therapeutics, Inc.Thyroid Eye Disease
Start: 2025-07-01End: 2026-05-28Updated: 2026-06-25

Phase 4

A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Not yet recruitingNCT07803679
AmgenAtheroma, Atherosclerotic Plaque, Coronary Artery Disease +1
Start: 2027-01-31End: 2029-04-30Target: 308Updated: 2026-09-10

Unknown Phase

Assessment of Injectable Medication Platforms
NCT05367531
Canadian Forces Health Services Centre OttawaAllergic Reaction, Bleeding, Overdose Antidote
Start: 2022-04-30End: 2025-01-01Target: 30Updated: 2023-02-08

Related Papers

Usability of Prefilled Syringe and Autoinjector for SB4 (An Etanercept Biosimilar) in Patients with Rheumatoid Arthritis.
2019-08-0111 citations